# FIREGEN BIOMEDICALS CO.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/firegen-biomedicals-co

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.fgbiomed.com
- Total disclosed funding: $14M
- Latest round: Series D (Aug 21, 2025)
- Investors on record: 11

## About

Based in Beijing, China, and established in 2016, FIREGEN BIOMEDICALS CO., LTD. is a biotechnology company that focuses on gene sequencing services. It has set up GMP plants and R&D and production bases in Shandong and Jiangsu, with branches in Tianjin, Shanghai, Jinan, Guangzhou, Nanjing, Wuhan, etc. In December 2022, it acquired the Kaifeng Kangbi'en Medical Laboratory. In May 2022, it obtained ISO9001 quality management system certification. In September 2023, FIREGEN BIOMEDICALS CO., LTD. raised more than CNY 100 million in series D funding co-led by new investors Beijing ZhiLai Investment Management, Jianchuang Medical Growth Fund, and returning investor GSR Ventures. The company's self-developed products include the FireAuto series of automated nucleic acid extractors, the FG0330 Viral DNA/RNA Total Nucleic Acid Extraction Kit, the FG0336 Plasma Free DNA Extraction Kit, the FG0323 Tissue Paraffin Section Genomic DNA Extraction Kit, the FG0510 Microbial Genomic DNA Extraction Kit and the Novel Coronavirus (SARS-CoV-2) Nucleic Acid Detection Kit. The sales network covers more than 30 countries and regions around the world. It mainly serves hospitals, pharmaceutical companies, research institutes, medical testing organizations, community hospitals, etc. It also provides medical laboratory services, science and innovation public services, and protein/antibody customization. The company will use the funds for the development and iteration of multiple fast detection instruments, multi-joint detection diagnostic reagents, and other products. 
In August 2025, FIREGEN BIOMEDICALS CO., LTD. raised a series D+ funding from new investors Herui Venture Capital, Zhuji Jingkai Chuangrong and other unspecified investors.

## Funding rounds

- Series D, Aug 21, 2025 — Zhuji Jingkai Chuangrong, Herui Venture Capital
- Series D, Sep 21, 2023, $14M — GSR Ventures, Beijing ZhiLai Investment Mangement, Jianchuang Medical Growth Fund
- Series C, Jan 30, 2022 — GSR Ventures, CAS Investment Management, Skyworth, Tianjin Kechuang, Zhongguancun Science City Capital, Beijing Zhongguan Longchengtianhe Investment Management
- Series A, Mar 28, 2019 — Beijing Haina Yourong Capital

## Investors

- Beijing Haina Yourong Capital (https://capitalatlas.ai/funds/beijing-haina-yourong-capital) — Series A
- GSR Ventures (https://capitalatlas.ai/funds/gsr-ventures) — Series C, Series D
- CAS Investment Management (https://capitalatlas.ai/funds/cas-investment-management) — Series C
- Skyworth (https://capitalatlas.ai/funds/skyworth) — Series C
- Tianjin Kechuang — Series C
- Zhongguancun Science City Capital (https://capitalatlas.ai/funds/zhongguancun-science-city-capital) — Series C
- Beijing Zhongguan Longchengtianhe Investment Management — Series C
- Beijing ZhiLai Investment Mangement — Series D
- Jianchuang Medical Growth Fund — Series D
- Zhuji Jingkai Chuangrong — Series D
- Herui Venture Capital (https://capitalatlas.ai/funds/herui-venture-capital) — Series D